The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions

The induction of antitumor immune responses by dendritic cell (DC)/tumor cell fusions can be modulated by their activation status. Our recent work reveals that the combination of Toll-like receptor 2 (TLR2) and TLR4 agonists promotes the immunogenicity of DC/tumor cell fusions, allowing them to over...

Descripción completa

Detalles Bibliográficos
Autores principales: Koido, Shigeo, Homma, Sadamu, Okamoto, Masato, Namiki, Yoshihisa, Takakura, Kazuki, Uchiyama, Kan, Kajihara, Mikio, Ohkusa, Toshifumi, Gong, Jianlin, Tajiri, Hisao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782132/
https://www.ncbi.nlm.nih.gov/pubmed/24073361
http://dx.doi.org/10.4161/onci.24660
_version_ 1782285519014592512
author Koido, Shigeo
Homma, Sadamu
Okamoto, Masato
Namiki, Yoshihisa
Takakura, Kazuki
Uchiyama, Kan
Kajihara, Mikio
Ohkusa, Toshifumi
Gong, Jianlin
Tajiri, Hisao
author_facet Koido, Shigeo
Homma, Sadamu
Okamoto, Masato
Namiki, Yoshihisa
Takakura, Kazuki
Uchiyama, Kan
Kajihara, Mikio
Ohkusa, Toshifumi
Gong, Jianlin
Tajiri, Hisao
author_sort Koido, Shigeo
collection PubMed
description The induction of antitumor immune responses by dendritic cell (DC)/tumor cell fusions can be modulated by their activation status. Our recent work reveals that the combination of Toll-like receptor 2 (TLR2) and TLR4 agonists promotes the immunogenicity of DC/tumor cell fusions, allowing them to overcome the immunosuppressive effects of transforming growth factor β1.
format Online
Article
Text
id pubmed-3782132
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-37821322013-09-26 The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions Koido, Shigeo Homma, Sadamu Okamoto, Masato Namiki, Yoshihisa Takakura, Kazuki Uchiyama, Kan Kajihara, Mikio Ohkusa, Toshifumi Gong, Jianlin Tajiri, Hisao Oncoimmunology Author's View The induction of antitumor immune responses by dendritic cell (DC)/tumor cell fusions can be modulated by their activation status. Our recent work reveals that the combination of Toll-like receptor 2 (TLR2) and TLR4 agonists promotes the immunogenicity of DC/tumor cell fusions, allowing them to overcome the immunosuppressive effects of transforming growth factor β1. Landes Bioscience 2013-07-01 2013-04-30 /pmc/articles/PMC3782132/ /pubmed/24073361 http://dx.doi.org/10.4161/onci.24660 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Koido, Shigeo
Homma, Sadamu
Okamoto, Masato
Namiki, Yoshihisa
Takakura, Kazuki
Uchiyama, Kan
Kajihara, Mikio
Ohkusa, Toshifumi
Gong, Jianlin
Tajiri, Hisao
The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions
title The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions
title_full The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions
title_fullStr The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions
title_full_unstemmed The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions
title_short The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions
title_sort combination of tlr2 and tlr4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782132/
https://www.ncbi.nlm.nih.gov/pubmed/24073361
http://dx.doi.org/10.4161/onci.24660
work_keys_str_mv AT koidoshigeo thecombinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT hommasadamu thecombinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT okamotomasato thecombinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT namikiyoshihisa thecombinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT takakurakazuki thecombinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT uchiyamakan thecombinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT kajiharamikio thecombinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT ohkusatoshifumi thecombinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT gongjianlin thecombinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT tajirihisao thecombinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT koidoshigeo combinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT hommasadamu combinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT okamotomasato combinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT namikiyoshihisa combinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT takakurakazuki combinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT uchiyamakan combinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT kajiharamikio combinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT ohkusatoshifumi combinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT gongjianlin combinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions
AT tajirihisao combinationoftlr2andtlr4agonistspromotestheimmunogenicityofdendriticcellcancercellfusions

Ejemplares similares